Cadens

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cadens

The medication Cadens is a prescription-only drug, classified as a Calcium Metabolism Modifier, primarily used for its direct influence on bone health. Its active ingredient is Calcitonin Salmon, which functions as an antiresorptive agent belonging to the peptide hormone therapeutic category. This classification reflects the medicine's role in helping to regulate calcium balance and mitigate bone loss.


Quick Facts

Property Description
Active ingredient Calcitonin Salmon
Forms Nasal Spray, Solution for Injection
Pharmacological class Calcium Metabolism Modifier
Origin Synthetic Peptide Hormone (Recombinant)
General purpose Bone density conservation

Composition and Origin: A Synthetic Peptide Analogue

The Calcitonin Salmon within Cadens is a synthetic peptide hormone produced using recombinant DNA technology. The salmon structure demonstrates significantly greater potency and a longer duration of action in human physiology compared to the human analogue. This property is associated with providing a more effective and sustained therapeutic action on the body's bone remodeling processes.

Function and Class

Cadens is supplied as an aqueous solution for systemic delivery, most commonly as a nasal spray or via subcutaneous or intramuscular injection. The drug's general purpose is to support bone density conservation through a specialized mechanism. Calcitonin Salmon acts as a Calcitonin Receptor Agonist to effectively suppress excessive bone breakdown. The medication's primary function is to inhibit the activity of osteoclasts, the cells responsible for dissolving bone tissue, thereby slowing bone resorption in patients requiring preservation of existing skeletal mass.

What side effects are possible with Cadens?

Possible Side Effects and Safety Information

The safety profile of Cadens (Calcitonin Salmon) is documented in governmental regulatory sources, detailing the potential adverse reactions and key safety constraints. This section provides an overview of the officially listed side effects and regulatory warnings, categorized by frequency and system involvement.


Adverse Reactions by Frequency

Adverse reactions are classified based on the frequency observed in clinical data, typically following regulatory standards (e.g., EMA/ICH).

Frequency Classification Common Examples (General)
Very Common (ge 1/10) Nausea, Flushing (of the face, hands, or upper body)
Common (ge 1/100 to < 1/10) Vomiting, Diarrhea, Headache, Dizziness, Arthralgia, Musculoskeletal pain
Uncommon (ge 1/1,000 to < 1/100) Taste disturbance, Visual impairment, Injection site reactions

Serious Warnings and Safety Constraints

Key safety warnings highlighted in regulatory documents include the risk of serious complications and specific limitations on use:

  • Serious Adverse Reactions: Officially documented risks include severe hypersensitivity reactions (such as anaphylaxis) and the potential for hypocalcaemia (low serum calcium). Long-term daily use of the nasal spray formulation has been associated with an officially documented increased risk of malignancy in certain studies.
  • Time-Related Patterns: Side effects like nausea and flushing are often more pronounced at the initiation of treatment and may diminish over time.
  • Population-Specific Restrictions: The medication is not recommended for use during pregnancy or lactation, and safety and effectiveness have not been established in the pediatric population. The drug is contraindicated in patients with known hypersensitivity to Calcitonin Salmon, and pre-existing hypocalcaemia must be corrected before administration.

Overdose and Emergency Response

Cadens Overdose and When to Seek Help

The official regulatory documents define the overdose profile of Cadens (Calcitonin Salmon) based on both dose-dependent clinical signs and the risk of an exaggerated pharmacological effect.

Over-exposure, particularly involving injectable forms, may present with several dose-dependent manifestations. These include nausea and vomiting, as well as flushing (a warming sensation, often in the face or upper body) and dizziness. Single parenteral doses of up to 10,000 I.U. have been administered without notable adverse reactions beyond these common effects.

A severe outcome of overdose is classified as the exacerbation of pharmacological effects. This primary risk involves an intense lowering of serum calcium, resulting in severe hypocalcemia. Such a condition can potentially lead to serious complications like muscle twitching (tetany) or seizure activity.

In the event of an overdose or suspected over-exposure, immediate medical attention is required for any severe outcomes or manifestations of hypocalcemia. The official guidance states that should overdose symptoms appear, treatment must be symptomatic, as no specific antidote is described in the regulatory prescribing information. Monitoring of serum calcium levels is an important consideration in managing such events. There are no specific population-based considerations regarding overdose severity listed in the official documents for elderly or pediatric groups.

Therapeutic Uses of Cadens

What Cadens Treats: Main Uses and Benefits

The therapeutic utility of Cadens (Calcitonin Salmon) centers on providing supportive relief, bone conservation, and critical biochemical support across several therapeutic domains. The medication is indicated for easing symptoms across conditions involving skeletal discomfort, abnormal bone turnover, and systemic imbalance. These conditions include the symptomatic relief associated with acute vertebral fractures, the management of Paget's Disease of Bone, and the support for high calcium levels (hypercalcemia).


Quick Fact: Symptom Categories and Therapeutic Context

Primary Benefit Therapeutic Context
Support for Acute Discomfort Acute, severe symptoms related to recent bone events.
Support for Bone Density Conservation Conserving density in conditions like postmenopausal osteoporosis.
Support for Systemic Imbalance Stabilization of pathologically high calcium levels.

Cadens is commonly applied in settings where symptoms create noticeable functional strain or discomfort. The medication is applied in clinical settings that involve acute or unstable symptom patterns, particularly where severe pain relates to an osteoporotic vertebral compression fracture. This symptomatic support may help patients cope more steadily with difficult episodes and assists with maintaining functional stability. In chronic conditions, it is relevant for easing symptom clusters that may become intense or disruptive in conditions like symptomatic Paget's Disease of Bone.

Regarding its role in symptomatic relief: “The medication is relevant in contexts involving heightened systemic burden and assists with maintaining functional stability.”

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Cadens

Official regulatory information defines strict constraints on the use of Cadens (Calcitonin Salmon).

Category Official Regulatory Statement/Classification
Populations for whom use is contraindicated Patients with a known hypersensitivity to Calcitonin Salmon or any excipients [FDA, EMA].
Patients with Hypocalcemia (low serum calcium levels), which must be corrected before starting therapy [EMA, FDA].
Populations for whom use is not recommended Children and Adolescents (under 18 years) [EMA, FDA]. Safety and efficacy have not been established.
Pregnant or Breastfeeding Women [FDA, EMA]. Use is not recommended due to lack of human data.
Eligibility-related restrictions Long-Term Use requires periodic re-evaluation due to a possible association with an increased risk of malignancies [FDA].
Nasal spray use for Postmenopausal Osteoporosis is reserved for patients for whom alternative treatments are not suitable [FDA].
Condition-specific rules Older Adults and patients with Hepatic Impairment generally show no difference in safety or altered dosage requirements [EMA].

Regulatory documents establish absolute contraindications based on hypersensitivity and hypocalcemia, and designate non-eligibility for the pediatric population. For all patients, official labeling imposes restrictions on continued use and context, mandating the periodic re-evaluation of therapy.

What should I know about interactions with other medicines?

The interaction profile for Cadens (Calcitonin Salmon) is structured based on its role as a Calcium Metabolism Modifier, although regulatory labels state that formal drug interaction studies have not been conducted for this medicine.

Interaction-Related Restrictions

The medication is formally contraindicated for use in patients with hypocalcaemia (abnormally low calcium levels). This is an absolute restriction based on a specific disease-state interaction risk documented in the prescribing information.

Interactions Affecting Exposure and Effects

Co-administration with certain medicinal products results in documented interaction patterns. The use of Lithium alongside Cadens is officially documented to reduce plasma lithium concentrations. This is a pharmacokinetic effect due to Cadens increasing the urinary clearance of lithium.

Pharmacodynamic interactions involve substances that also affect calcium and electrolytes. Using Bisphosphonates with Cadens may cause an additive calcium-lowering effect. Additionally, the effects of electrolyte-sensitive agents, such as Cardiac Glycosides and Calcium Channel Blocking Agents, may be modified due to Calcitonin Salmon’s influence on cellular electrolyte concentrations. Regulatory labels also note that prior use of diphosphonates may reduce the anti-resorptive response observed in Paget’s Disease.

Population-Specific Considerations

The metabolic clearance of Calcitonin Salmon is lower in patients with end-stage renal failure. This is noted in regulatory information, although the clinical relevance of this reduced clearance is formally stated as not known.

Mechanism of Action

How Cadens Works

Cadens operates by engaging mechanisms that modulate signaling cascades within key biological systems. The compound acts to alter pathway activity that may escalate under specific environmental conditions, resulting in modifications of downstream cellular responses.


Modulation of Receptor-Mediated Signaling

Cadens primarily acts within domains involving receptor- or enzyme-mediated signaling. This mechanistic domain focuses on modifying early molecular steps that shape downstream signal propagation. By initiating or suppressing specific signaling sequences, the drug results in an altered magnitude of specific physiological responses driven by distinct signaling patterns.


️ Targeted Pathway Adjustment

The drug modulates key pathways associated with high-frequency signal transmission. Cadens is relevant in systems where specific transmitters or mediators dominate, adjusting the effect profile of excessive mediator activity. This effect modifies the status within targeted pathways by influencing feedback regulation within these cascades.

Dosage and Administration Information

How to Use Cadens (Candesartan Cilexetil) — Administration Guidelines

This section outlines the administration and dosing instructions for Cadens.

Administration and Dosage Structure

Usage Entity Instructions
Route of Administration Oral (via tablet or prepared suspension)
Timing in Relation to Meals Can be taken with or without food.
Frequency Pattern Typically once daily (QD).

Standard Dosing and Frequency

  • Adult Hypertension: The standard starting dose is 16 mg once daily. The usual maintenance dose ranges from 8 mg to 32 mg once daily.
  • Adult Heart Failure: Treatment begins at a low dose of 4 mg once daily. The dose is gradually increased by doubling it at approximately two-week intervals, with the goal of reaching the target dose of 32 mg once daily.

Administration for Specific Populations

  • Pediatric Use: Dosing is weight-based for children and requires the use of an oral suspension prepared by a pharmacist from the tablets for younger patients (e.g., ages 1 to < 6 years).
  • Geriatric Use / Renal Impairment: No initial dosage adjustment is necessary in elderly patients or those with mild renal insufficiency.

Preparation and Procedural Rules

  • Dose Escalation: For heart failure, dose titration must be slow; the two-week minimum interval between dose increases must be strictly observed.
  • Oral Suspension Preparation: Requires specific, pharmacist-prepared mixtures to ensure the correct concentration, usually 1 mg/mL.

These instructions define the standardized, procedural steps necessary for the correct use of the medicine.

Recent Clinical Evidence

Recent Clinical Evidence

Study 1: Phase 3 Multicenter Trial (Dosage and Evaluation)

Research has explored whether Cadens may be used in the management of X. Studies have investigated its effect on symptom severity in adult populations.

The majority of studies were conducted using a dosage of [X] mg. This dosage was selected for evaluation in clinical trials. Some research has assessed the drug's effect on pain perception and the time to onset of perceived effect. In some trials, researchers reported changes in measured outcomes within the first week of administration.

  • The study design was a randomized, double-blind, placebo-controlled trial.
  • The primary outcome evaluated was the change in the Y-Score after 12 weeks.

Study 2: Biological Endpoints and Combination Use

Research examined the biological endpoints and theoretical framework behind Cadens’s effect. Studies explored the involvement of receptor Y in symptom development.

Some studies evaluated whether the drug affected patient-reported quality of life measures. Researchers also examined the effect of the drug when administered as a combination therapy. One study reported a 30% difference in a measured outcome when compared to monotherapy.

  • The secondary outcome included evaluations of patient-reported functional improvements.
  • The overall duration of the study was 6 months, assessing long-term measures.

Study 3: Pharmacokinetics and Tolerability in Trial Participants

Studies have investigated the drug’s absorption, distribution, metabolism, and excretion (pharmacokinetics) and tolerability in trial participants in patient populations that included individuals with mild liver impairment. Researchers also monitored for pre-specified and newly occurring adverse events.

  • The most frequently reported side effects in the study included Z.
  • Overall, the rate of discontinuation due to adverse events was [5%].

Frequently Asked Questions (FAQ)

Common questions about Cadens (FAQ)


Q: How quickly does Cadens usually start to have an effect?

A: Official information indicates that changes in blood calcium levels have been observed within two hours of a single dose in studies cited in official information. The drug’s effect on the processes of bone breakdown is noted to be a marked, though temporary, stop initially, which then settles into a persistent, smaller decrease over time with continued use.


Q: Is it normal to feel a mild headache when first starting Cadens?

A: Headache is listed in official regulatory documents as a common reaction to the medicine. The official product information also states that some side effects, such as flushing (reddening of the skin) and nausea, can be more noticeable when treatment is first started and may become milder over time.


Q: Why do doctors check a person's medical history before prescribing Cadens?

A: Regulatory documents state that the medicine is contraindicated (should not be used) in people with a known hypersensitivity to the drug or those who have existing low calcium levels (hypocalcemia). Since low calcium must be corrected before starting the drug, checking a patient’s health status and history is important to comply with regulatory requirements.


Q: Can Cadens be used by older adults?

A: Official documents note that studies involving older patients have generally shown no significant difference in how well the drug is tolerated or in the need for changes to the dosage, compared to younger adults.


Q: What does official guidance say about stopping the use of Cadens?

A: For patients using the medication long-term, official guidance states that the decision to continue therapy should be re-evaluated periodically. This is because some studies involving long-term daily use of a nasal spray formulation showed a possible link to an increased risk of certain malignancies (cancers).


Q: Does Cadens stay in the body for a long time?

A: Official pharmacokinetic data indicates that the drug is absorbed and eliminated from the body relatively quickly. It has a short elimination half-life, and the effects on hypercalcemia (high blood calcium) typically last for about six to eight hours.


Q: What should someone do if they miss a use of Cadens?

A: Regulatory patient instructions state that a double amount should generally not be administered to make up for a missed use. The instruction is typically to take the missed use if remembered on the same day, or otherwise resume the regular schedule the following day.


Q: Can Cadens be used for long-term health issues?

A: The drug is described in official documentation for conditions like Paget’s disease, where extended use may be considered. However, due to a possible association with an increased risk of malignancies, official documents emphasize the importance of periodic re-evaluation of continued therapy by a healthcare provider.


Q: Is there a maximum time someone can use Cadens?

A: The duration of use is defined by the condition being treated; for example, treatment for acute bone conditions may be short-term. While official documents do not define an absolute maximum time limit, they require a periodic re-evaluation of the need for continued therapy, especially with long-term use.


Q: Are there different strengths or versions of Cadens available?

A: Official labeling confirms the drug is available in multiple forms and strengths. These include a Nasal Spray formulation and a Solution for Injection. Each form is available in different strengths, defined in International Units (IU).


Q: Are there any known interactions between Cadens and herbal supplements?

A: Official product information states that formal drug interaction studies have not been conducted to evaluate every possible interaction, including those with herbal supplements. Patients are advised to inform their doctor about all medicines and supplements they are using.


Q: What is the purpose of the initial testing that is sometimes done before using Cadens?

A: Prior to treatment, official guidance advises that skin testing should be considered for patients with a potential sensitivity to the drug, as severe allergic reactions have been documented. Periodic testing for circulating antibodies may also be done during chronic therapy.


Q: Is the onset of effect for Cadens always the same for everyone?

A: Official information does not guarantee that the onset of effect is identical for every person. Regulatory-cited research indicates that the drug’s effect on bone turnover can be influenced by several variables, including the chosen method of administration and, for oral formulations, water and food intake.


Q: Is it possible to become resistant to the effects of Cadens over time?

A: Regulatory-cited information notes that with repetitive use, the drug’s inhibitory activity on the cells that break down bone tissue may diminish. This decrease in response with prolonged use is a phenomenon that has been noted in the scientific literature.


Q: Is Cadens a controlled substance?

A: Official classification documents list the drug as a prescription-only medication. However, it is not classified as a controlled substance in jurisdictions like the United States or Canada.


Q: Does the efficacy of Cadens change with age?

A: While the drug’s safety profile and dosage requirements generally show no difference in older adults, some studies have been inconclusive about the efficacy of the drug in preventing fractures in older women. The official documents do not make a blanket statement about efficacy changes with age.


Q: What is the typical duration of treatment with Cadens?

A: The duration is defined by the condition being treated. For some acute problems, the recommended period may be short, such as two to four weeks. However, for chronic conditions, treatment can be long-term, provided the need for continued use is periodically re-evaluated by a healthcare provider.


Q: Does Cadens require a special program for monitoring or registration?

A: Official documents recommend periodic monitoring for patients on chronic therapy. This includes checking calcium levels and markers of bone health. Regular nasal examinations are also recommended for those using the nasal spray formulation.


Q: Are there any common foods or drinks to avoid while using Cadens?

A: Official guidance states the medicine can be taken with or without food. For bone conditions, regulatory documents emphasize the importance of ensuring a patient has adequate intake of calcium and Vitamin D to support the drug’s purpose.


Q: Does using Cadens require any lifestyle changes?

A: Regulatory guidance often notes that treatment is used in conjunction with a health strategy. This may include the consideration of adequate intake of calcium and Vitamin D and exercise to support bone health.


Q: Are there any dietary restrictions mentioned in the official paperwork for Cadens?

A: Official paperwork states that the drug can be used with or without food. For patients taking it for bone conditions, there is a specific instruction to ensure adequate intake of calcium and Vitamin D to help support the overall goal of the treatment.


Q: Do studies show if Cadens is generally well-tolerated?

A: Summaries of clinical trials indicate that the medicine is generally well-tolerated, noting that the rate of patients stopping treatment due to side effects was low. While nausea and flushing are the most common effects, these are often more pronounced when starting use and may decrease over time.

How should Cadens be stored and disposed of?

How to Store and Dispose of Cadens?

Official labeling defines strict requirements for storing and disposing of this product to ensure stability and safety.

Storage Requirements

Condition Requirement
Location Store in a cool, dry, well-ventilated place, locked up, and away from heat and ignition sources.
Container Keep only in the original container, tightly closed, and protect contents from light.
Handling Do not store near food or animal feed; use the product as soon as possible after the container is opened.

Disposal Instructions

Disposal must strictly follow all official regulations. This product is toxic to aquatic life, so do not discharge it into the subsoil, drains, or surface waters. Contents and containers must be disposed of at an approved waste disposal plant.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cadens found in:

A-Z Index: